

# Glenda M Halliday

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/7383115/publications.pdf](https://exaly.com/author-pdf/7383115/publications.pdf)

Version: 2024-02-01

676  
papers

75,092  
citations

660

119  
h-index

758

242  
g-index

759  
all docs

759  
docs citations

759  
times ranked

47969  
citing authors

#	ARTICLE	IF	CITATIONS
1	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	4.3	4,805
2	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2005, 65, 1863-1872.	1.1	4,671
3	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.1	2,997
4	The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. <i>Movement Disorders</i> , 2008, 23, 837-844.	4.3	1,842
5	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , The, 2019, 18, 1091-1102.	10.3	1,596
6	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611.	4.3	1,083
7	Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. <i>Brain</i> , 2013, 136, 2419-2431.	8.0	1,024
8	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. <i>Acta Neuropathologica</i> , 2007, 114, 5-22.	7.9	998
9	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. <i>Brain</i> , 2019, 142, 1503-1527.	8.0	956
10	Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity. <i>Brain Research Reviews</i> , 1987, 12, 117-165.	9.0	888
11	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. <i>Acta Neuropathologica</i> , 2010, 119, 1-4.	7.9	880
12	Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. <i>Lancet Neurology</i> , The, 2009, 8, 1150-1157.	10.3	766
13	Selective neuronal vulnerability in Parkinson disease. <i>Nature Reviews Neuroscience</i> , 2017, 18, 101-113.	10.6	764
14	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	4.3	644
15	Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr $\alpha$ -synuclein mutation. <i>Annals of Neurology</i> , 2001, 49, 313-319.	5.8	635
16	Missing pieces in the Parkinson's disease puzzle. <i>Nature Medicine</i> , 2010, 16, 653-661.	29.9	632
17	Evidence for $\alpha$ -synuclein prions causing multiple system atrophy in humans with parkinsonism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E5308-17.	7.5	600
18	Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. <i>Brain</i> , 2002, 125, 391-403.	8.0	592

#	ARTICLE	IF	CITATIONS
19	Clinicopathological correlates in frontotemporal dementia. <i>Annals of Neurology</i> , 2004, 56, 399-406.	5.8	555
20	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021, 7, 47.	18.6	513
21	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. <i>Nature Genetics</i> , 2010, 42, 234-239.	20.2	501
22	The cerebral cortex is damaged in chronic alcoholics. <i>Neuroscience</i> , 1997, 79, 983-998.	2.4	487
23	Reduced glucocerebrosidase is associated with increased $\alpha$ -synuclein in sporadic Parkinson's disease. <i>Brain</i> , 2014, 137, 834-848.	8.0	416
24	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. <i>Acta Neuropathologica</i> , 2016, 131, 87-102.	7.9	401
25	Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. <i>Brain</i> , 2002, 125, 2431-2445.	8.0	394
26	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2013, 70, 727.	9.3	392
27	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462.	4.3	391
28	Operational criteria for the classification of chronic alcoholics: identification of Wernicke's encephalopathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 62, 51-60.	6.0	389
29	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. <i>Acta Neuropathologica</i> , 2009, 117, 15-18.	7.9	388
30	Glia: Initiators and progressors of pathology in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 6-17.	4.3	388
31	Neuropathology underlying clinical variability in patients with synucleinopathies. <i>Acta Neuropathologica</i> , 2011, 122, 187-204.	7.9	366
32	Survival in frontotemporal dementia. <i>Neurology</i> , 2003, 61, 349-354.	1.1	362
33	Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. <i>Annals of Neurology</i> , 1990, 27, 373-385.	5.8	355
34	Degeneration of anterior thalamic nuclei differentiates alcoholics with amnesia. <i>Brain</i> , 2000, 123, 141-154.	8.0	355
35	The progression of pathology in longitudinally followed patients with Parkinson's disease. <i>Acta Neuropathologica</i> , 2008, 115, 409-415.	7.9	347
36	Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. <i>Brain Research</i> , 1990, 510, 104-107.	2.3	329

#	ARTICLE	IF	CITATIONS
37	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , The, 2014, 13, 686-699.	10.3	327
38	A possible role for humoral immunity in the pathogenesis of Parkinson's disease. <i>Brain</i> , 2005, 128, 2665-2674.	8.0	320
39	Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease. <i>Progress in Neurobiology</i> , 2005, 75, 109-124.	5.8	319
40	The pathological basis of semantic dementia. <i>Brain</i> , 2005, 128, 1984-1995.	8.0	313
41	The frontotemporal dementia-motor neuron disease continuum. <i>Lancet</i> , The, 2016, 388, 919-931.	12.1	308
42	Alpha-synuclein biology in Lewy body diseases. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 73.	6.3	307
43	An inflammatory review of Parkinson's disease. <i>Progress in Neurobiology</i> , 2002, 68, 325-340.	5.8	302
44	Neuropathologic correlates of white matter hyperintensities. <i>Neurology</i> , 2008, 71, 804-811.	1.1	302
45	The neurobiological basis of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 634-650.	4.3	300
46	±-Synucleinopathy phenotypes. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S62-S67.	2.2	295
47	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.	4.3	289
48	Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene. <i>Brain</i> , 2000, 123, 880-893.	8.0	280
49	PART is part of Alzheimer disease. <i>Acta Neuropathologica</i> , 2015, 129, 749-756.	7.9	267
50	Cortical Lewy body pathology in the diagnosis of dementia. <i>Acta Neuropathologica</i> , 2001, 102, 355-363.	7.9	266
51	Staging disease severity in pathologically confirmed cases of frontotemporal dementia. <i>Neurology</i> , 2003, 60, 1005-1011.	1.1	248
52	Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. <i>Brain</i> , 2014, 137, 2493-2508.	8.0	240
53	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	20.2	229
54	Regional Specificity of Brain Atrophy in Huntington's Disease. <i>Experimental Neurology</i> , 1998, 154, 663-672.	4.1	226

#	ARTICLE	IF	CITATIONS
55	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2010, 120, 33-41.	7.9	226
56	Language-Associated Cortical Regions Are Proportionally Larger in the Female Brain. <i>Archives of Neurology</i> , 1997, 54, 171-176.	4.5	225
57	Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing. <i>Genome Medicine</i> , 2019, 11, 54.	8.5	223
58	Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. <i>Brain</i> , 2000, 123, 1410-1421.	8.0	220
59	Monocyte Chemoattractant Protein-1 Plays a Dominant Role in the Chronic Inflammation Observed in Alzheimer's Disease. <i>Brain Pathology</i> , 2009, 19, 392-398.	4.1	213
60	Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology. <i>Acta Neuropathologica</i> , 2017, 133, 303-319.	7.9	212
61	Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus. <i>Neuroscience</i> , 1991, 42, 757-775.	2.4	205
62	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 64-74.	10.3	205
63	New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 865-870.	6.0	203
64	TDP-43 proteinopathies: a new wave of neurodegenerative diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 86-95.	6.0	197
65	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	10.3	196
66	Copper pathology in vulnerable brain regions in Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 858-866.	3.1	194
67	GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. <i>Annals of Neurology</i> , 2005, 58, 829-839.	5.8	193
68	α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. <i>Brain</i> , 2005, 128, 2654-2664.	8.0	192
69	Progression in Frontotemporal Dementia. <i>Archives of Neurology</i> , 2006, 63, 1627.	4.5	192
70	c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. <i>Human Molecular Genetics</i> , 2014, 23, 2858-2879.	3.0	190
71	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608.	4.3	188
72	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014, 23, 6139-6146.	3.0	186

#	ARTICLE	IF	CITATIONS
73	Inflammation is genetically implicated in Parkinson's disease. <i>Neuroscience</i> , 2015, 302, 89-102.	2.4	186
74	Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3161.	4.2	184
75	Alzheimer's Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2000, 27, 1-8.	2.0	181
76	Are Parkinson's Disease with dementia and Dementia with lewy Bodies the Same Entity?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004, 17, 137-145.	2.5	181
77	Degeneration in Different Parkinsonian Syndromes Relates to Astrocyte Type and Astrocyte Protein Expression. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 1073-1083.	1.8	179
78	Molecular Pathogenesis of the Tauopathies. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2019, 14, 239-261.	23.1	179
79	Identifying the Pattern of Olfactory Deficits in Parkinson Disease Using the Brief Smell Identification Test. <i>Archives of Neurology</i> , 2003, 60, 545.	4.5	177
80	Brain shrinkage in alcoholics: a decade on and what have we learned?. <i>Progress in Neurobiology</i> , 1999, 58, 381-387.	5.8	176
81	Neuroinflammation in frontotemporal dementia. <i>Nature Reviews Neurology</i> , 2019, 15, 540-555.	10.0	174
82	Topography of brain atrophy during normal aging and alzheimer's disease. <i>Neurobiology of Aging</i> , 1996, 17, 513-521.	3.1	171
83	Neuronal loss in functional zones of the cerebellum of chronic alcoholics with and without Wernicke's encephalopathy. <i>Neuroscience</i> , 1999, 91, 429-438.	2.4	171
84	p25 Relocalizes in Oligodendroglia from Myelin to Cytoplasmic Inclusions in Multiple System Atrophy. <i>American Journal of Pathology</i> , 2007, 171, 1291-1303.	4.1	171
85	Degeneration of the central median-parafascicular complex in Parkinson's disease. <i>Annals of Neurology</i> , 2000, 47, 345-352.	5.8	170
86	The comparative biology of neuromelanin and lipofuscin in the human brain. <i>Cellular and Molecular Life Sciences</i> , 2008, 65, 1669-1682.	5.4	169
87	Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration's motor neuron disease. <i>Annals of Neurology</i> , 2010, 68, 639-649.	5.8	169
88	Visual misperceptions and hallucinations in Parkinson's disease: Dysfunction of attentional control networks?. <i>Movement Disorders</i> , 2011, 26, 2154-2159.	4.3	169
89	Pathologically proven frontotemporal dementia presenting with severe amnesia. <i>Brain</i> , 2005, 128, 597-605.	8.0	168
90	Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. <i>Journal of Comparative Neurology</i> , 1996, 364, 121-150.	1.9	166

#	ARTICLE	IF	CITATIONS
91	Reduced T helper and B lymphocytes in Parkinson's disease. <i>Journal of Neuroimmunology</i> , 2012, 252, 95-99.	2.4	166
92	Structural heterogeneity of $\alpha$ -synuclein fibrils amplified from patient brain extracts. <i>Nature Communications</i> , 2019, 10, 5535.	13.0	166
93	Eating and hypothalamus changes in behavioral variant frontotemporal dementia. <i>Annals of Neurology</i> , 2011, 69, 312-319.	5.8	163
94	Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. <i>Acta Neuropathologica</i> , 2002, 103, 370-376.	7.9	162
95	Tricks of the mind: Visual hallucinations as disorders of attention. <i>Progress in Neurobiology</i> , 2014, 116, 58-65.	5.8	161
96	Focal demyelination in Alzheimer's disease and transgenic mouse models. <i>Acta Neuropathologica</i> , 2010, 119, 567-577.	7.9	159
97	In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease. <i>Brain</i> , 2012, 135, 3015-3025.	8.0	159
98	Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1033-1037.	6.0	153
99	Milestones in Parkinson's disease—Clinical and pathologic features. <i>Movement Disorders</i> , 2011, 26, 1015-1021.	4.3	153
100	Chronic alcohol consumption does not cause hippocampal neuron loss in humans. <i>Hippocampus</i> , 1997, 7, 78-87.	2.1	151
101	Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1554-1563.	3.1	151
102	Gut-brain axis and the spread of $\alpha$ -synuclein pathology: Vagal highway or dead end?. <i>Movement Disorders</i> , 2019, 34, 307-316.	4.3	150
103	Lipid Pathway Alterations in Parkinson's Disease Primary Visual Cortex. <i>PLoS ONE</i> , 2011, 6, e17299.	2.5	150
104	Cytoarchitecture of the human dorsal raphe nucleus. <i>Journal of Comparative Neurology</i> , 1990, 301, 147-161.	1.9	148
105	A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. <i>Brain Structure and Function</i> , 2012, 217, 591-612.	2.3	147
106	Parkinson's Disease Is Not Simply a Prion Disorder. <i>Journal of Neuroscience</i> , 2017, 37, 9799-9807.	3.8	147
107	Anti-inflammatory Drugs Protect Against Alzheimer Disease at Low Doses. <i>Archives of Neurology</i> , 2000, 57, 1586-91.	4.5	146
108	Loss of vasopressin-immunoreactive neurons in alcoholics is dose-related and time-dependent. <i>Neuroscience</i> , 1996, 72, 699-708.	2.4	139

#	ARTICLE	IF	CITATIONS
109	Spontaneous regression of human melanoma/nonmelanoma skin cancer: Association with infiltrating CD4 <sup>+</sup> T cells. <i>World Journal of Surgery</i> , 1995, 19, 352-358.	1.4	138
110	Thalamic changes in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S152-S155.	2.2	137
111	Regression in basal cell carcinoma: an immunohistochemical analysis. <i>British Journal of Dermatology</i> , 1994, 130, 1-8.	1.7	135
112	Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. <i>Brain</i> , 2005, 128, 1259-1266.	8.0	135
113	Comparative anatomy of the ventromedial mesencephalic tegmentum in the rat, cat, monkey and human. <i>Journal of Comparative Neurology</i> , 1986, 252, 423-445.	1.9	133
114	Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1639-1647.	4.3	132
115	Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. <i>Acta Neuropathologica</i> , 2021, 141, 159-172.	7.9	132
116	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. <i>Acta Neuropathologica</i> , 2014, 127, 407-418.	7.9	128
117	Biomarkers in dementia: clinical utility and new directions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1426-1434.	6.0	128
118	Localization of copper and copper transporters in the human brain. <i>Metallomics</i> , 2013, 5, 43-51.	2.5	127
119	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. <i>Brain</i> , 2002, 125, 789-800.	8.0	126
120	Distribution of monoamine-synthesizing neurons in the human medulla oblongata. <i>Journal of Comparative Neurology</i> , 1988, 273, 301-317.	1.9	121
121	Generation and characterization of novel conformation-specific monoclonal antibodies for $\alpha$ -synuclein pathology. <i>Neurobiology of Disease</i> , 2015, 79, 81-99.	4.5	121
122	Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72, 747-751.	6.0	120
123	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. <i>Brain</i> , 2018, 141, 521-534.	8.0	120
124	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	4.3	120
125	Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 518-526.	4.3	119
126	Specific A10 Dopaminergic Nuclei in the Midbrain Degenerate in Parkinson's Disease. <i>Experimental Neurology</i> , 1997, 144, 202-213.	4.1	118



#	ARTICLE	IF	CITATIONS
127	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. <i>Annals of Neurology</i> , 2000, 47, 718-728.	5.8	117
128	Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. <i>Brain</i> , 2003, 126, 814-826.	8.0	115
129	Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 1166-1173.	4.3	114
130	The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. <i>Human Brain Mapping</i> , 2014, 35, 2206-2219.	3.7	114
131	Neuropathology of $\alpha$ -synuclein propagation and Braak hypothesis. <i>Movement Disorders</i> , 2016, 31, 152-160.	4.3	113
132	Changes in the solubility and phosphorylation of $\alpha$ -synuclein over the course of Parkinson's disease. <i>Acta Neuropathologica</i> , 2011, 121, 695-704.	7.9	111
133	Cerebellar atrophy in Parkinson's disease and its implication for network connectivity. <i>Brain</i> , 2016, 139, 845-855.	8.0	111
134	Neuronal network disintegration: common pathways linking neurodegenerative diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1234-1241.	6.0	110
135	Selective cell death in neurodegeneration: Why are some neurons spared in vulnerable regions?. <i>Progress in Neurobiology</i> , 2010, 92, 316-329.	5.8	109
136	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. <i>Archives of Neurology</i> , 2011, 68, 488.	4.5	109
137	<i>C9ORF72</i> repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. <i>Neurology</i> , 2012, 79, 995-1001.	1.1	109
138	Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. <i>British Journal of Dermatology</i> , 2002, 146, 810-815.	1.7	108
139	Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. <i>Acta Neuropathologica</i> , 2004, 108, 515-523.	7.9	107
140	Pyramidal Cell Loss in Motor Cortices in Huntington's Disease. <i>Neurobiology of Disease</i> , 2002, 10, 378-386.	4.5	106
141	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 251-257.	1.8	106
142	$\beta$ and tau prion-like activities decline with longevity in the Alzheimer's disease human brain. <i>Science Translational Medicine</i> , 2019, 11, .	13.3	106
143	A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. <i>Brain</i> , 2005, 128, 2272-2280.	8.0	101
144	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 862-871.	0.7	100

#	ARTICLE	IF	CITATIONS
145	Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation. <i>Acta Neuropathologica</i> , 1992, 84, 638-50.	7.9	98
146	Variation in hippocampal neuron number with age and brain volume. <i>Cerebral Cortex</i> , 1998, 8, 710-718.	3.1	98
147	An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. <i>Acta Neuropathologica</i> , 2006, 111, 329-340.	7.9	98
148	pH measurement as quality control on human <i>post mortem</i> brain tissue: a study of the BrainNet Europe consortium. <i>Neuropathology and Applied Neurobiology</i> , 2009, 35, 329-337.	3.2	98
149	Genome-wide analyses as part of the international FTL D-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTL D. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	7.9	96
150	Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. <i>Journal of Clinical Neuroscience</i> , 1996, 3, 52-60.	1.6	95
151	Quantification of cortical atrophy in a case of progressive fluent aphasia. <i>Brain</i> , 1996, 119, 181-190.	8.0	95
152	Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. <i>Acta Neuropathologica</i> , 2010, 120, 777-788.	7.9	95
153	TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. <i>Brain</i> , 2015, 138, 3110-3122.	8.0	95
154	Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. <i>EMBO Reports</i> , 2018, 19, .	4.5	95
155	Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. <i>Brain</i> , 2004, 127, 2214-2220.	8.0	94
156	Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. <i>Acta Neuropathologica</i> , 2012, 124, 373-382.	7.9	94
157	Analysis of DNA methylation associates the cystine-glutamate antiporter SLC7A11 with risk of Parkinson's disease. <i>Nature Communications</i> , 2020, 11, 1238.	13.0	94
158	Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 133-137.	4.3	93
159	An action spectrum for ultraviolet radiation-induced immunosuppression in humans. <i>British Journal of Dermatology</i> , 2011, 164, no-no.	1.7	93
160	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology</i> , The, 2016, 15, 546-548.	10.3	93
161	Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain. <i>Metallomics</i> , 2017, 9, 1447-1455.	2.5	93
162	A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. <i>British Journal of Dermatology</i> , 2016, 175, 1073-1075.	1.7	92

#	ARTICLE	IF	CITATIONS
163	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 22.	6.3	92
164	Mutations in progranulin explain atypical phenotypes with variants in MAPT. <i>Brain</i> , 2006, 129, 3124-3126.	8.0	91
165	Pathology and hippocampal atrophy in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2017, 16, 862-864.	10.3	91
166	Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing. <i>Science Advances</i> , 2022, 8, eabm5386.	10.8	91
167	SUBSTANCE P-CONTAINING NEURONS IN THE MESOPONTINE TEGMENTUM ARE SEVERELY AFFECTED IN PARKINSON'S DISEASE. <i>Brain</i> , 1991, 114, 2253-2267.	8.0	89
168	Specific temporoparietal gyral atrophy reflects the pattern of language dissolution in Alzheimer's disease. <i>Brain</i> , 1999, 122, 675-686.	8.0	89
169	MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 26697.	3.4	89
170	Multiple Biological Pathways Link Cognitive Lifestyle to Protection from Dementia. <i>Biological Psychiatry</i> , 2012, 71, 783-791.	1.3	86
171	Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease. <i>Scientific Reports</i> , 2018, 8, 15446.	3.4	86
172	Cytoarchitecture of serotonin-synthesizing neurons in the pontine tegmentum of the human brain. <i>Synapse</i> , 1991, 7, 301-320.	1.2	85
173	Cytokine profiles in spontaneously regressing basal cell carcinomas. <i>British Journal of Dermatology</i> , 2000, 143, 91-98.	1.7	85
174	LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients. <i>Movement Disorders</i> , 2019, 34, 406-415.	4.3	85
175	DNA methylation of the <i>MAPT</i> gene in Parkinson's disease cohorts and modulation by vitamin E <i>In Vitro</i> . <i>Movement Disorders</i> , 2014, 29, 1606-1614.	4.3	84
176	Motor cortical function determines prognosis in sporadic ALS. <i>Neurology</i> , 2016, 87, 513-520.	1.1	84
177	Genetic contributions to Parkinson's disease. <i>Brain Research Reviews</i> , 2004, 46, 44-70.	9.0	83
178	Striatal Î²-amyloid in dementia with Lewy bodies but not Parkinson's disease. <i>Journal of Neural Transmission</i> , 2011, 118, 713-719.	2.9	83
179	GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. <i>Journal of Comparative Neurology</i> , 2012, 520, 2591-2607.	1.9	83
180	Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 65.	5.4	83

#	ARTICLE	IF	CITATIONS
181	Practical considerations for the use of the optical disector in estimating neuronal number. <i>Journal of Neuroscience Methods</i> , 1994, 51, 83-89.	2.6	82
182	Autophagy activation promotes clearance of $\beta$ -synuclein inclusions in fibril-seeded human neural cells. <i>Journal of Biological Chemistry</i> , 2019, 294, 14241-14256.	3.5	82
183	Topical nicotinamide modulates cellular energy metabolism and provides broad-spectrum protection against ultraviolet radiation-induced immunosuppression in humans. <i>British Journal of Dermatology</i> , 2009, 161, 1357-1364.	1.7	81
184	Cerebellar Integrity in the Amyotrophic Lateral Sclerosis - Frontotemporal Dementia Continuum. <i>PLoS ONE</i> , 2014, 9, e105632.	2.5	81
185	Characterization of circular RNA landscape in multiple system atrophy brain. <i>Journal of Neurochemistry</i> , 2016, 139, 485-496.	4.0	81
186	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , 2016, 38, 214.e7-214.e10.	3.1	81
187	ALS/FTLD: experimental models and reality. <i>Acta Neuropathologica</i> , 2017, 133, 177-196.	7.9	81
188	Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson's disease brain. <i>Acta Neuropathologica</i> , 2017, 134, 113-127.	7.9	81
189	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	4.3	81
190	Distribution of brain atrophy in behavioral variant frontotemporal dementia. <i>Journal of the Neurological Sciences</i> , 2005, 232, 83-90.	0.6	80
191	Longitudinal white matter changes in frontotemporal dementia subtypes. <i>Human Brain Mapping</i> , 2014, 35, 3547-3557.	3.7	80
192	Psychiatric disorders in <i>C9orf72</i> kindreds. <i>Neurology</i> , 2018, 91, e1498-e1507.	1.1	80
193	Temporal evolution of microglia and $\beta$ -synuclein accumulation following foetal grafting in Parkinson's disease. <i>Brain</i> , 2019, 142, 1690-1700.	8.0	79
194	Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. , 2006, , 99-103.		79
195	Systems-Based Analyses of Brain Regions Functionally Impacted in Parkinson's Disease Reveals Underlying Causal Mechanisms. <i>PLoS ONE</i> , 2014, 9, e102909.	2.5	79
196	Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. <i>Brain</i> , 2003, 126, 827-840.	8.0	78
197	An Improved High-Throughput Lipid Extraction Method for the Analysis of Human Brain Lipids. <i>Lipids</i> , 2013, 48, 307-318.	1.7	78
198	Abnormal connectivity between the default mode and the visual system underlies the manifestation of visual hallucinations in Parkinson's disease: a task-based fMRI study. <i>Npj Parkinson's Disease</i> , 2015, 1, 15003.	5.4	78

#	ARTICLE	IF	CITATIONS
199	Parvalbumin as an anatomical marker for discrete subregions of the ambiguous complex in the rat. <i>Neuroscience Letters</i> , 1993, 160, 101-105.	2.1	77
200	Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. <i>Movement Disorders</i> , 2016, 31, 889-897.	4.3	76
201	Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease. <i>Experimental Neurology</i> , 2017, 298, 202-209.	4.1	76
202	MSA prions exhibit remarkable stability and resistance to inactivation. <i>Acta Neuropathologica</i> , 2018, 135, 49-63.	7.9	76
203	Anti-melanin antibodies are increased in sera in Parkinson's disease. <i>Experimental Neurology</i> , 2009, 217, 297-301.	4.1	75
204	ABCA7 Mediates Phagocytic Clearance of Amyloid- $\beta^2$ in the Brain. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 569-584.	2.7	75
205	Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. <i>Frontiers in Molecular Neuroscience</i> , 2014, 7, 57.	2.9	74
206	Neuropathologic assessment of participants in two multicenter longitudinal observational studies: The Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). <i>Neuropathology</i> , 2015, 35, 390-400.	1.3	74
207	Eating behavior in frontotemporal dementia. <i>Neurology</i> , 2015, 85, 1310-1317.	1.1	74
208	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. <i>Annals of Neurology</i> , 2017, 81, 46-57.	5.8	74
209	Localization of immunoreactivity for Deleted in Colorectal Cancer (DCC), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents. <i>Neuroscience</i> , 2005, 131, 671-681.	2.4	73
210	Visual hallucinations in Parkinson's disease: Theoretical models. <i>Movement Disorders</i> , 2014, 29, 1591-1598.	4.3	73
211	Physiological changes in neurodegeneration – mechanistic insights and clinical utility. <i>Nature Reviews Neurology</i> , 2018, 14, 259-271.	10.0	73
212	No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. <i>Movement Disorders</i> , 2009, 24, 1519-1523.	4.3	72
213	Immunohistochemical evidence for macroautophagy in neurones and endothelial cells in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2010, 36, 312-319.	3.2	72
214	Spread of pathology in amyotrophic lateral sclerosis: assessment of phosphorylated TDP-43 along axonal pathways. <i>Acta Neuropathologica Communications</i> , 2015, 3, 47.	5.3	72
215	Pedigree with frontotemporal lobar degeneration – motor neuron disease and Tau DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. <i>BMC Neurology</i> , 2008, 8, 32.	1.8	71
216	$\text{A}\beta^2$ -dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimer's disease. <i>Nature Communications</i> , 2015, 6, 8836.	13.0	71

#	ARTICLE	IF	CITATIONS
217	Brainstem Serotonergic Neurons in Chronic Alcoholics With and Without the Memory Impairment of Korsakoff's Psychosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 1993, 52, 567-579.	1.8	70
218	Two novel presenilin-1 mutations (Ser169Leu and Pro436Gln) associated with very early onset Alzheimer's disease. <i>NeuroReport</i> , 1998, 9, 3335-3339.	1.2	70
219	Role of the Long Non-Coding RNA MAPT-AS1 in Regulation of Microtubule Associated Protein Tau (MAPT) Expression in Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0157924.	2.5	70
220	Effect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease. <i>Archives of Neurology</i> , 2000, 57, 831.	4.5	69
221	White matter loss in healthy ageing: A postmortem analysis. <i>Neurobiology of Aging</i> , 2009, 30, 1288-1295.	3.1	68
222	Parkinson's progression prediction using machine learning and serum cytokines. <i>Npj Parkinson's Disease</i> , 2019, 5, 14.	5.4	68
223	Cortical Inflammation in Alzheimer Disease but Not Dementia With Lewy Bodies. <i>Archives of Neurology</i> , 2000, 57, 817.	4.5	67
224	Substantia nigra echomorphology in the healthy very old: Correlation with motor slowing. <i>NeuroImage</i> , 2007, 34, 1054-1059.	4.4	67
225	Multiple system atrophy prions retain strain specificity after serial propagation in two different Tg(SNCA <sup>A53T</sup> ) mouse lines. <i>Acta Neuropathologica</i> , 2019, 137, 437-454.	7.9	67
226	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinson's Disease</i> , 2021, 11, 395-404.	2.9	67
227	Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 673-686.	2.8	66
228	CYLD is a causative gene for frontotemporal dementia " amyotrophic lateral sclerosis. <i>Brain</i> , 2020, 143, 783-799.	8.0	66
229	Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2014, 2, 150.	5.3	65
230	The neural correlates and clinical characteristics of psychosis in the frontotemporal dementia continuum and the C9orf72 expansion. <i>NeuroImage: Clinical</i> , 2017, 13, 439-445.	2.8	65
231	FTD and ALS " translating mouse studies into clinical trials. <i>Nature Reviews Neurology</i> , 2015, 11, 360-366.	10.0	64
232	$\beta$ -Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. <i>Proteomics</i> , 2006, 6, 6566-6577.	3.0	63
233	ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2013, 1, 11.	5.3	63
234	Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain. <i>Translational Psychiatry</i> , 2017, 7, e1003-e1003.	4.9	63

#	ARTICLE	IF	CITATIONS
235	Corticobasal syndrome with tau pathology. <i>Movement Disorders</i> , 2001, 16, 656-667.	4.3	62
236	Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLTDP and ALS. <i>Acta Neuropathologica</i> , 2015, 130, 661-678.	7.9	62
237	Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework. <i>Brain</i> , 2020, 143, 31-46.	8.0	62
238	The Subthalamic Nucleus in Parkinson's Disease and Progressive Supranuclear Palsy. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 132-142.	1.8	61
239	Identifying severely atrophic cortical subregions in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2003, 24, 797-806.	3.1	61
240	Dolichol is the major lipid component of human substantia nigra neuromelanin. <i>Journal of Neurochemistry</i> , 2005, 92, 990-995.	4.0	61
241	Pick bodies in a family with presenilin-1 Alzheimer's disease. <i>Annals of Neurology</i> , 2005, 57, 139-143.	5.8	61
242	Distribution of substance P-like immunoreactive neurons in the human medulla oblongata: Co-localization with monoamine-synthesizing neurons. <i>Synapse</i> , 1988, 2, 353-370.	1.2	60
243	Cell loss in the nucleus basalis is related to regional cortical atrophy in Alzheimer's disease. <i>Neuroscience</i> , 1997, 78, 641-652.	2.4	60
244	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. <i>Genome Biology</i> , 2021, 22, 90.	9.1	60
245	Transforming growth factor- $\beta^2$ produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin. <i>International Immunology</i> , 2001, 13, 1147-1154.	4.0	59
246	Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat. <i>Behavioural Brain Research</i> , 2003, 139, 105-113.	2.3	59
247	The left human speech-processing cortex is thinner but longer than the right. <i>Laterality</i> , 2003, 8, 247-260.	1.0	59
248	Evidence for specific phases in the development of human neuromelanin. <i>Neurobiology of Aging</i> , 2006, 27, 506-512.	3.1	59
249	Protective properties of lysozyme on $\beta^2$ -amyloid pathology: implications for Alzheimer disease. <i>Neurobiology of Disease</i> , 2015, 83, 122-133.	4.5	59
250	Progressive Supranuclear Palsy Affects both the Substantia Nigra Pars Compacta and Reticulata. <i>Experimental Neurology</i> , 1997, 144, 183-192.	4.1	58
251	Idiopathic generalized epilepsy. <i>Neurology</i> , 2000, 55, 1101-1106.	1.1	58
252	Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2006, 154, 72-78.	1.7	58

#	ARTICLE	IF	CITATIONS
253	Variable phenotype of Alzheimer's disease with spastic paraparesis. <i>Journal of Neurochemistry</i> , 2008, 104, 573-583.	4.0	58
254	Human Homologs to Brainstem Nuclei Identified in Other Animals as Revealed by Acetylcholinesterase Activity. , 1990, , 149-202.		57
255	Substantia Nigra Pars Reticulata Neurons in Parkinson's Disease. <i>Experimental Neurology</i> , 1996, 5, 49-55.	1.6	56
256	Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease?. <i>Movement Disorders</i> , 2009, 24, 833-838.	4.3	56
257	The substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration. <i>Journal of Chemical Neuroanatomy</i> , 2016, 76, 98-107.	2.2	56
258	Distribution of Pathology in Frontal Variant Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 63-70.	2.7	55
259	Dopamine depletion alters macroscopic network dynamics in Parkinson's disease. <i>Brain</i> , 2019, 142, 1024-1034.	8.0	55
260	Quantitative analysis of the variability of substantia nigra pigmented cell clusters in the human. <i>Neuroscience</i> , 1995, 68, 539-551.	2.4	54
261	Diffuse Lewy body disease: clinical features in nine cases without coexistent Alzheimer's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 60, 531-538.	6.0	54
262	Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria. <i>Acta Neuropathologica</i> , 2002, 104, 72-78.	7.9	54
263	Presenilin-1 Mutation L271V Results in Altered Exon 8 Splicing and Alzheimer's Disease with Non-cored Plaques and No Neuritic Dystrophy. <i>Journal of Biological Chemistry</i> , 2003, 278, 6748-6754.	3.5	54
264	Comparison of motor, cognitive, and behavioral features in progressive supranuclear palsy and Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 632-638.	4.3	54
265	Low Serum Progranulin Predicts the Presence of Mutations: A Prospective Study. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 981-984.	2.7	54
266	Beyond the temporal pole: limbic memory circuit in the semantic variant of primary progressive aphasia. <i>Brain</i> , 2014, 137, 2065-2076.	8.0	54
267	Selective hippocampal neuron loss in dementia with Lewy bodies. <i>Annals of Neurology</i> , 2002, 51, 125-128.	5.8	54
268	The distribution of neuropeptide Y-like immunoreactive neurons in the human medulla oblongata. <i>Neuroscience</i> , 1988, 26, 179-191.	2.4	53
269	Calbindin D28k-containing neurons are restricted to the medial substantia nigra in humans. <i>Neuroscience</i> , 1995, 65, 87-91.	2.4	53
270	Neurofibrillary degeneration and cell loss in the nucleus basalis in comparison to cortical Alzheimer pathology. <i>Neurobiology of Aging</i> , 1998, 19, 297-306.	3.1	53



#	ARTICLE	IF	CITATIONS
271	Relationship between hippocampal volume and CA1 neuron loss in brains of humans with and without Alzheimer's disease. <i>Neuroscience Letters</i> , 2004, 361, 9-12.	2.1	53
272	Intralaminar nuclei of the thalamus in Lewy body diseases. <i>Brain Research Bulletin</i> , 2009, 78, 97-104.	3.0	52
273	Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival. <i>Journal of Neurology</i> , 2016, 263, 1593-1603.	3.8	52
274	Cellular and regional vulnerability in frontotemporal tauopathies. <i>Acta Neuropathologica</i> , 2019, 138, 705-727.	7.9	52
275	Circular RNAs: The Brain Transcriptome Comes Full Circle. <i>Trends in Neurosciences</i> , 2020, 43, 752-766.	8.8	52
276	Significant loss of pyramidal neurons in the angular gyrus of patients with Huntington's disease. <i>Neuropathology and Applied Neurobiology</i> , 1997, 23, 492-495.	3.2	51
277	A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 191-202.	2.2	50
278	Glucocerebrosidase deficits in sporadic Parkinson disease. <i>Autophagy</i> , 2014, 10, 1350-1351.	11.6	50
279	Progression in Behavioral Variant Frontotemporal Dementia. <i>JAMA Neurology</i> , 2015, 72, 1501.	9.3	50
280	Isoform-specific proteolysis of apolipoprotein-E in the brain. <i>Neurobiology of Aging</i> , 2011, 32, 257-271.	3.1	49
281	Genetic Polymorphisms in Sigma-1 Receptor and Apolipoprotein E Interact to Influence the Severity of Alzheimers Disease. <i>Current Alzheimer Research</i> , 2011, 8, 765-770.	1.5	49
282	Smallâ€vessel disease in patients with Parkinson's disease: A clinicopathological study. <i>Movement Disorders</i> , 2012, 27, 1506-1512.	4.3	49
283	Classification of FTL D-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. <i>Acta Neuropathologica Communications</i> , 2013, 1, 33.	5.3	49
284	Distinctive pathological mechanisms involved in primary progressiveâ€aphasias. <i>Neurobiology of Aging</i> , 2016, 38, 82-92.	3.1	49
285	Glial fibrillary acidic protein (GFAP) immunohistochemistry in human cortex: a quantitative study using different antisera. <i>Neuroscience Letters</i> , 1996, 209, 29-32.	2.1	48
286	Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer's disease and dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2001, 101, 616-624.	7.9	48
287	The neural basis of semantic memory: Evidence from semantic dementia. <i>Neurobiology of Aging</i> , 2009, 30, 2043-2052.	3.1	48
288	Systemic metabolism in frontotemporal dementia. <i>Neurology</i> , 2014, 83, 1812-1818.	1.1	48

#	ARTICLE	IF	CITATIONS
289	Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 773-783.	2.7	48
290	A comparative analysis of neurons containing catecholamine-synthesizing enzymes and neuropeptide Y in the ventrolateral medulla of rats, guinea-pigs and cats. <i>Neuroscience</i> , 1991, 43, 531-550.	2.4	47
291	Arylsulfatase A, a genetic modifier of Parkinson's disease, is an $\alpha$ -synuclein chaperone. <i>Brain</i> , 2019, 142, 2845-2859.	8.0	47
292	Anterior cingulate integrity: Executive and neuropsychiatric features in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1262-1267.	4.3	46
293	Quantitation and three-dimensional reconstruction of Ch4 nucleus in the human basal forebrain. <i>Synapse</i> , 1993, 15, 1-16.	1.2	45
294	Clinical phenotypes in autopsy-confirmed Pick disease. <i>Neurology</i> , 2011, 76, 253-259.	1.1	45
295	Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease. <i>Neurobiology of Aging</i> , 2013, 34, 873-886.	3.1	45
296	Early disruption of glial communication via connexin gap junction in multiple sclerosis, $\alpha$ -synuclein's disease and neuromyelitis optica. <i>Neuropathology</i> , 2015, 35, 469-480.	1.3	45
297	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016, 31, 1623-1627.	4.3	45
298	Can we clinically diagnose dementia with Lewy bodies yet?. <i>Translational Neurodegeneration</i> , 2013, 2, 4.	8.1	44
299	Measurement of LRRK2 and Ser910/935 Phosphorylated LRRK2 in Peripheral Blood Mononuclear Cells from Idiopathic Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2013, 3, 145-152.	2.9	44
300	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018, 141, 2895-2907.	8.0	44
301	Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. <i>Journal of Neurology</i> , 2004, 251, 1098-104.	3.8	43
302	Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy. <i>Movement Disorders</i> , 2011, 26, 256-263.	4.3	43
303	Tyrosine hydroxylase-containing neurons in the supraoptic and paraventricular nuclei of the adult human. <i>Brain Research</i> , 1988, 461, 75-86.	2.3	42
304	Neurofibrillary tangles in chronic alcoholics. <i>Neuropathology and Applied Neurobiology</i> , 1995, 21, 312-318.	3.2	42
305	Practical measures to simplify the Braak tangle staging method for routine pathological screening. <i>Acta Neuropathologica</i> , 2000, 99, 199-208.	7.9	42
306	What is the dominant $\alpha$ 2 species in human brain tissue? A review. <i>Neurotoxicity Research</i> , 2005, 7, 29-41.	2.7	42

#	ARTICLE	IF	CITATIONS
307	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II. Journal of Neuropathology and Experimental Neurology, 2007, 66, 329-336.	1.8	42
308	Unique Transcriptome Patterns of the White and Grey Matter Corroborate Structural and Functional Heterogeneity in the Human Frontal Lobe. PLoS ONE, 2013, 8, e78480.	2.5	42
309	ABCA5 Regulates Amyloid- $\beta^2$ Peptide Production and is Associated with Alzheimer's Disease Neuropathology. Journal of Alzheimer's Disease, 2014, 43, 857-869.	2.7	42
310	Lipid dysfunction and pathogenesis of multiple system atrophy. Acta Neuropathologica Communications, 2014, 2, 15.	5.3	42
311	Early-onset axonal pathology in a novel $\alpha$ -synuclein transgenic mouse model of frontotemporal lobar degeneration. Neuropathology and Applied Neurobiology, 2015, 41, 906-925.	3.2	42
312	Decline in Proliferation and Immature Neuron Markers in the Human Subependymal Zone during Aging: Relationship to EGF- and FGF-Related Transcripts. Frontiers in Aging Neuroscience, 2016, 8, 274.	3.5	42
313	LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies. Movement Disorders, 2017, 32, 423-432.	4.3	42
314	Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. Neurobiology of Disease, 2017, 97, 179-188.	4.5	42
315	Neuronal intranuclear inclusion disease is genetically heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 1716-1725.	3.7	42
316	Serotonin-like immunoreactive cells and fibres in the rat ventromedial mesencephalic tegmentum. Brain Research Bulletin, 1989, 22, 725-735.	3.0	41
317	Substance P-containing neurons in the pontomesencephalic tegmentum of the human brain. Neuroscience, 1990, 39, 81-96.	2.4	41
318	The nucleus basalis (Ch4) in the alcoholic Wernicke-Korsakoff syndrome: reduced cell number in both amnesic and non-amnesic patients. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 63, 315-320.	6.0	41
319	A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy. Brain, 2000, 123, 724-732.	8.0	41
320	A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Molecular Neurodegeneration, 2016, 11, 61.	11.7	41
321	Multisite Assessment of Aging-Related Tau Astroglial Pathology (ARTAG). Journal of Neuropathology and Experimental Neurology, 2017, 76, 605-619.	1.8	41
322	Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 486-495.	3.7	41
323	Ubiquitin-positive achromatic neurons in corticobasal degeneration. Acta Neuropathologica, 1995, 90, 68-75.	7.9	40
324	Human-based studies on $\alpha$ -synuclein deposition and relationship to Parkinson's disease symptoms. Experimental Neurology, 2008, 209, 12-21.	4.1	40

#	ARTICLE	IF	CITATIONS
325	Subtle gait and balance impairments occur in idiopathic rapid eye movement sleep behavior disorder. <i>Movement Disorders</i> , 2019, 34, 1374-1380.	4.3	40
326	Uncovering pathophysiological changes in frontotemporal dementia using serum lipids. <i>Scientific Reports</i> , 2020, 10, 3640.	3.4	40
327	Dementia in long-term Parkinson's disease patients: a multicentre retrospective study. <i>Npj Parkinson's Disease</i> , 2020, 6, 2.	5.4	40
328	The locus coeruleus and memory: a study of chronic alcoholics with and without the memory impairment of Korsakoff's psychosis. <i>Brain Research</i> , 1992, 598, 33-37.	2.3	39
329	Simplified neuropathological diagnosis of dementia with Lewy bodies. <i>Neuropathology and Applied Neurobiology</i> , 1998, 24, 195-201.	3.2	39
330	Cortical degeneration associated with phonologic and semantic language impairments in AD. <i>Neurology</i> , 2001, 56, 944-950.	1.1	39
331	Increased ATP-Binding Cassette Transporter A1 Expression in Alzheimer's Disease Hippocampal Neurons. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 193-205.	2.7	39
332	Assessment of amyloid $\beta$ in pathologically confirmed frontotemporal dementia syndromes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 10-20.	2.6	39
333	PARK Genes Link Mitochondrial Dysfunction and Alpha-Synuclein Pathology in Sporadic Parkinson's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 612476.	3.8	39
334	The Internal Globus Pallidus Is Affected in Progressive Supranuclear Palsy and Parkinson's Disease. <i>Experimental Neurology</i> , 1999, 158, 135-142.	4.1	38
335	Inhibition of nitric oxide and reactive oxygen species production improves the ability of a sunscreen to protect from sunburn, immunosuppression and photocarcinogenesis. <i>British Journal of Dermatology</i> , 2006, 155, 408-415.	1.7	38
336	Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers. <i>Brain</i> , 2018, 141, 486-495.	8.0	38
337	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	1.7	38
338	Neurofilament-Immunoreactive Neurons in Alzheimer's Disease and Dementia with Lewy Bodies. <i>Neurobiology of Disease</i> , 2002, 9, 249-257.	4.5	37
339	Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. <i>Movement Disorders</i> , 2015, 30, 796-804.	4.3	37
340	Lipidomics Analysis of Behavioral Variant Frontotemporal Dementia: A Scope for Biomarker Development. <i>Frontiers in Neurology</i> , 2018, 9, 104.	2.5	37
341	Topical Retinoic Acid Enhances, and a Dark Tan Protects, from Subedermal Solar-Simulated Photocarcinogenesis. <i>Journal of Investigative Dermatology</i> , 2000, 114, 923-927.	0.7	36
342	Hemorrhage is uncommon in new Alzheimer family with Flemish amyloid precursor protein mutation. <i>Neurology</i> , 2004, 63, 1613-1617.	1.1	36

#	ARTICLE	IF	CITATIONS
343	Evidence for specific phases in the development of human neuromelanin. <i>Journal of Neural Transmission</i> , 2006, 113, 721-728.	2.9	36
344	An emerging role for LRRK2 in the immune system. <i>Biochemical Society Transactions</i> , 2012, 40, 1134-1139.	3.4	36
345	Exploring Myelin Dysfunction in Multiple System Atrophy. <i>Experimental Neurobiology</i> , 2014, 23, 337-344.	1.6	36
346	Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord. <i>Brain</i> , 2022, 145, 3108-3130.	8.0	36
347	Lipid pathway dysfunction is prevalent in patients with Parkinson's disease. <i>Brain</i> , 2022, 145, 3472-3487.	8.0	36
348	Rostrocaudal differences in morphology and neurotransmitter content of cells in the subretrofacial vasomotor nucleus. <i>Journal of the Autonomic Nervous System</i> , 1992, 38, 117-137.	2.0	35
349	The external globus pallidus in patients with Parkinson's disease and progressive supranuclear palsy. <i>Movement Disorders</i> , 1999, 14, 626-633.	4.3	35
350	Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 374-387.	3.2	35
351	Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. <i>Journal of Neural Transmission</i> , 2009, 116, 1243-1251.	2.9	35
352	Transcriptome analysis of grey and white matter cortical tissue in multiple system atrophy. <i>Neurogenetics</i> , 2015, 16, 107-122.	1.5	35
353	Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 979-989.	3.2	35
354	Immune responses in the Parkinson's disease brain. <i>Neurobiology of Disease</i> , 2022, 168, 105700.	4.5	35
355	Mechanisms of cell death in cholinergic basal forebrain neurons in chronic alcoholics. <i>Metabolic Brain Disease</i> , 1995, 10, 81-91.	2.9	34
356	Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's Disease. <i>Movement Disorders</i> , 2007, 22, 982-989.	4.3	34
357	Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheimer's disease. <i>Neuroscience</i> , 2012, 210, 363-374.	2.4	34
358	Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. <i>Scientific Reports</i> , 2016, 6, 31391.	3.4	34
359	Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques. <i>Neurobiology of Disease</i> , 2004, 15, 115-119.	4.5	33
360	Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD). <i>Neurobiology of Disease</i> , 2015, 82, 445-454.	4.5	33

#	ARTICLE	IF	CITATIONS
361	<i>SIRT1</i> is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 361-379.	3.2	33
362	The underacknowledged PPA-ALS. <i>Neurology</i> , 2019, 92, e1354-e1366.	1.1	33
363	Differences in regional brain atrophy in genetic forms of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 387-393.	3.1	32
364	Parkin Co-regulated Gene (PACRG) is regulated by the ubiquitin-proteasomal system and is present in the pathological features of parkinsonian diseases. <i>Neurobiology of Disease</i> , 2007, 27, 238-247.	4.5	32
365	Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 831-838.	2.6	32
366	$\beta$ -Synuclein Regulates Neuronal Cholesterol Efflux. <i>Molecules</i> , 2017, 22, 1769.	3.9	32
367	Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. <i>Scientific Reports</i> , 2020, 10, 13741.	3.4	32
368	Intraneuronal advanced glycation endproducts in presenilin-1 Alzheimer's disease. <i>NeuroReport</i> , 2002, 13, 601-604.	1.2	31
369	The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. <i>Experimental Neurology</i> , 2003, 184, 530-535.	4.1	31
370	Cognitive, Extrapyramidal, and Magnetic Resonance Imaging Predictors of Functional Impairment in Nondemented Older Community Dwellers: The Sydney Older Person Study. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 3-10.	2.9	31
371	A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 171-179.	2.6	31
372	Selective loss of oxytocin and vasopressin in the hypothalamus in early Huntington disease: a case study. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 843-848.	3.2	31
373	Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with <i>ATXN2</i> intermediate repeat expansions. <i>Annals of Neurology</i> , 2016, 79, 295-305.	5.8	31
374	Targeted, High-Resolution RNA Sequencing of Non-coding Genomic Regions Associated With Neuropsychiatric Functions. <i>Frontiers in Genetics</i> , 2019, 10, 309.	2.3	31
375	Analysis of staining methods for different cortical plaques in Alzheimer's disease. <i>Acta Neuropathologica</i> , 1994, 87, 174-186.	7.9	30
376	Chronic Alcoholics without Wernicke-Korsakoff Syndrome or Cirrhosis Do Not Lose Serotonergic Neurons in the Dorsal Raphe Nucleus. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 61-66.	2.5	30
377	Srp20 regulates TrkB pre-mRNA splicing to generate TrkB <sup>Shc</sup> transcripts with implications for Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2012, 123, 159-171.	4.0	30
378	Changes in Sphingomyelin Level Affect Alpha-Synuclein and ABCA5 Expression. <i>Journal of Parkinson's Disease</i> , 2012, 2, 41-46.	2.9	30

#	ARTICLE	IF	CITATIONS
379	Validation of the Psychosis and Hallucinations Questionnaire in Non-demented Patients with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 175-181.	1.7	30
380	von Economo Neuron Density and Thalamus Volumes in Behavioral Deficits in Frontotemporal Dementia Cases with and without a C9ORF72 Repeat Expansion. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 701-709.	2.7	30
381	Chronic traumatic encephalopathy in two former Australian National Rugby League players. <i>Acta Neuropathologica Communications</i> , 2019, 7, 97.	5.3	30
382	Apolipoprotein D Upregulation in Alzheimer's Disease but Not Frontotemporal Dementia. <i>Journal of Molecular Neuroscience</i> , 2019, 67, 125-132.	2.4	30
383	Defining early changes in Alzheimer's disease from RNA sequencing of brain regions differentially affected by pathology. <i>Scientific Reports</i> , 2021, 11, 4865.	3.4	30
384	Preliminary Evidence Suggesting Delayed Development in the Hypoglossal and Vagal Nuclei of SIDS Infants: A Necropsy Study. <i>Journal of Child Neurology</i> , 1992, 7, 44-49.	1.7	29
385	Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. <i>Journal of Neurochemistry</i> , 2005, 95, 599-608.	4.0	29
386	Increased Ndfip1 in the Substantia Nigra of Parkinsonian Brains Is Associated with Elevated Iron Levels. <i>PLoS ONE</i> , 2014, 9, e87119.	2.5	29
387	Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 24, 89-94.	2.2	29
388	Accelerated aging exacerbates a pre-existing pathology in a tau transgenic mouse model. <i>Aging Cell</i> , 2017, 16, 377-386.	6.7	29
389	Region- and Cell-specific Aneuploidy in Brain Aging and Neurodegeneration. <i>Neuroscience</i> , 2018, 374, 326-334.	2.4	29
390	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	4.5	29
391	Catecholaminergic Neurons. , 1990, , 1023-1049.		29
392	Serotonin and alcohol-related brain damage. <i>Metabolic Brain Disease</i> , 1995, 10, 25-30.	2.9	28
393	Phosphorylation of Apolipoprotein-E at an Atypical Protein Kinase CK2 PSD/E Site in Vitro. <i>Biochemistry</i> , 2005, 44, 7346-7353.	2.6	28
394	FAS-Dependent Cell Death in $\alpha$ -Synuclein Transgenic Oligodendrocyte Models of Multiple System Atrophy. <i>PLoS ONE</i> , 2013, 8, e55243.	2.5	28
395	Heritability in frontotemporal dementia: more missing pieces?. <i>Journal of Neurology</i> , 2014, 261, 2170-2177.	3.8	28
396	Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis. <i>Acta Neuropathologica Communications</i> , 2017, 5, 76.	5.3	28

#	ARTICLE	IF	CITATIONS
397	Further evidence for an association between a mutation in the APP gene and Lewy body formation. <i>Neuroscience Letters</i> , 1997, 227, 49-52.	2.1	27
398	Ubiquitin-positive inclusions and progression of pathology in frontotemporal dementia and motor neurone disease identifies a group with mainly early pathology. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 83-91.	3.2	27
399	Excessive dopamine neuron loss in progressive supranuclear palsy. <i>Movement Disorders</i> , 2008, 23, 607-610.	4.3	27
400	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 74, 126-138.	6.6	27
401	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018, 90, 74-82.	1.1	27
402	Reduced adult neurogenesis is associated with increased macrophages in the subependymal zone in schizophrenia. <i>Molecular Psychiatry</i> , 2021, 26, 6880-6895.	8.1	27
403	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 5.	5.3	27
404	Effect of Chronic Alcohol Consumption on the Human Locus Coeruleus. <i>Alcoholism: Clinical and Experimental Research</i> , 1994, 18, 1491-1496.	2.5	26
405	New face of neuromelanin. , 2006, , 119-123.		26
406	Antigen-Epitope Retrieval To Facilitate Proteomic Analysis of Formalin-Fixed Archival Brain Tissue. <i>Analytical Chemistry</i> , 2006, 78, 7216-7221.	6.7	26
407	P25 $\beta$ immunoreactive but $\beta$ -synuclein immunonegative neuronal inclusions in multiple system atrophy. <i>Acta Neuropathologica</i> , 2006, 111, 193-195.	7.9	26
408	Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimer's disease. <i>Acta Neuropathologica</i> , 2009, 117, 19-29.	7.9	26
409	Pathological Staging of Frontotemporal Lobar Degeneration. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 379-383.	2.4	26
410	DNA extraction from fresh-frozen and formalin-fixed, paraffinembedded human brain tissue. <i>Neuroscience Bulletin</i> , 2013, 29, 649-654.	3.5	26
411	High expression of long intervening non-coding RNA OLMALINC in the human cortical white matter is associated with regulation of oligodendrocyte maturation. <i>Molecular Brain</i> , 2015, 8, 2.	3.0	26
412	Strand-specific RNA-sequencing analysis of multiple system atrophy brain transcriptome. <i>Neuroscience</i> , 2016, 322, 234-250.	2.4	26
413	Levels of glial cell line-derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in Parkinson's disease. <i>Brain Pathology</i> , 2019, 29, 813-825.	4.1	26
414	Clinical and Biological Correlates of White Matter Hyperintensities in Patients With Behavioral-Variant Frontotemporal Dementia and Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1743-e1754.	1.1	26



#	ARTICLE	IF	CITATIONS
415	Apolipoprotein-E forms dimers in human frontal cortex and hippocampus. <i>BMC Neuroscience</i> , 2010, 11, 23.	1.8	25
416	The case of a 48 year-old woman with bizarre and complex delusions. <i>Nature Reviews Neurology</i> , 2010, 6, 175-179.	10.0	25
417	Nicotinamide reduces photodynamic therapy-induced immunosuppression in humans. <i>British Journal of Dermatology</i> , 2012, 167, 631-636.	1.7	25
418	Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T $\alpha$ -synuclein mutation. <i>Translational Neurodegeneration</i> , 2012, 1, 2.	8.1	25
419	Transcriptional profiling of multiple system atrophy cerebellar tissue highlights differences between the parkinsonian and cerebellar sub-types of the disease. <i>Acta Neuropathologica Communications</i> , 2020, 8, 76.	5.3	25
420	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. <i>Brain</i> , 2022, 145, 1598-1609.	8.0	25
421	Severe Anterograde Amnesia with Extensive Hippocampal Degeneration in a Case of Rapidly Progressive Frontotemporal Dementia.. <i>Neurocase</i> , 2001, 7, 57-64.	0.7	24
422	Mitochondrial DNA haplogroups J and K are not protective for Parkinson's disease in the Australian community. <i>Movement Disorders</i> , 2009, 24, 290-292.	4.3	24
423	Effect of age on proliferation-regulating factors in human adult neurogenic regions. <i>Journal of Neurochemistry</i> , 2010, 115, 956-964.	4.0	24
424	Substantia Nigra, Ventral Tegmental Area, and Retrorubral Fields. , 2012, , 439-455.		24
425	Frontotemporal dementia-amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1-q12.2: genetic, clinical and neuropathological analysis. <i>Acta Neuropathologica</i> , 2013, 125, 523-533.	7.9	24
426	Impulsivity, decreased social exploration, and executive dysfunction in a mouse model of frontotemporal dementia. <i>Neurobiology of Learning and Memory</i> , 2016, 130, 34-43.	2.0	24
427	Accumulation of dysfunctional SOD1 protein in Parkinson's disease is not associated with mutations in the SOD1 gene. <i>Acta Neuropathologica</i> , 2018, 135, 155-156.	7.9	24
428	Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2085-2093.	4.3	24
429	Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. <i>Brain</i> , 2002, 125, 789-800.	8.0	24
430	Substantia Nigra and Locus Coeruleus. , 2004, , 449-463.		23
431	Terra incognita-cerebellar contributions to neuropsychiatric and cognitive dysfunction in behavioral variant frontotemporal dementia. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 121.	3.5	23
432	Aneuploidy in Lewy body diseases. <i>Neurobiology of Aging</i> , 2015, 36, 1253-1260.	3.1	23

#	ARTICLE	IF	CITATIONS
433	ROCK1 Is Associated with Alzheimer's Disease-Specific Plaques, as well as Enhances Autophagosome Formation But not Autophagic A $\beta$ Clearance. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 253.	3.8	23
434	Expanding the phenotypic associations of globular glial tau subtypes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 6-13.	2.6	23
435	Cross-examining candidate genes implicated in multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2019, 7, 117.	5.3	23
436	Predictors of survival and progression in behavioural variant frontotemporal dementia. <i>European Journal of Neurology</i> , 2019, 26, 774-779.	3.5	23
437	Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. <i>Npj Parkinson's Disease</i> , 2022, 8, 34.	5.4	23
438	Reproducible sampling regimen for specific cortical regions: application to speech-associated areas. <i>Journal of Neuroscience Methods</i> , 1996, 67, 43-51.	2.6	22
439	Organization of Human Brain Stem Nuclei. , 2004, , 267-320.		22
440	Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration. <i>Movement Disorders</i> , 2005, 20, 34-39.	4.3	22
441	Is Seladin-1 Really a Selective Alzheimer's Disease Indicator?. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 35-39.	2.7	22
442	Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. <i>Movement Disorders</i> , 2013, 28, 1351-1359.	4.3	22
443	Re-evaluating the glio-centric view of multiple system atrophy by highlighting the neuronal involvement: Figure 1. <i>Brain</i> , 2015, 138, 2116-2119.	8.0	22
444	Four groups of tyrosine hydroxylase-immunoreactive neurons in the ventrolateral medulla of rats, guinea-pigs and cats identified on the basis of chemistry, topography and morphology. <i>Neuroscience</i> , 1991, 43, 551-568.	2.4	21
445	The dorsal, posterodorsal, and ventral tegmental nuclei: A cyto- and chemoarchitectonic study in the human. <i>Journal of Comparative Neurology</i> , 1992, 318, 117-137.	1.9	21
446	The relationships between mild cognitive impairment and phenotype in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2015, 1, 15015.	5.4	21
447	Mannose 6-Phosphate Receptor Is Reduced in -Synuclein Overexpressing Models of Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0160501.	2.5	21
448	Aphasia in Progressive Supranuclear Palsy: As Severe as Progressive Non-Fluent Aphasia. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 705-715.	2.7	21
449	Expression of tyrosine hydroxylase isoforms and phosphorylation at serine 40 in the human nigrostriatal system in Parkinson's disease. <i>Neurobiology of Disease</i> , 2019, 130, 104524.	4.5	21
450	TDP-43 levels in the brain tissue of ALS cases with and without C9ORF72 or ATXN2 gene expansions. <i>Neurology</i> , 2019, 93, e1748-e1755.	1.1	21

#	ARTICLE	IF	CITATIONS
451	Increased Tau Phosphorylation in Motor Neurons From Clinically Pure Sporadic Amyotrophic Lateral Sclerosis Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 605-614.	1.8	21
452	Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies. <i>Acta Neuropathologica Communications</i> , 2019, 7, 195.	5.3	21
453	Assessing the role of nocturnal core body temperature dysregulation as a biomarker of neurodegeneration. <i>Journal of Sleep Research</i> , 2020, 29, e12939.	3.3	21
454	Clinical features of Lewy body dementia: insights into diagnosis and pathophysiology. <i>Journal of Neurology</i> , 2020, 267, 380-389.	3.8	21
455	Adaptive structural changes in the motor cortex and white matter in Parkinson's disease. <i>Acta Neuropathologica</i> , 2022, 144, 861-879.	7.9	21
456	Regulation of the Skin Immune System by Retinoids During Carcinogenesis. <i>Journal of Investigative Dermatology</i> , 1992, 99, S83-S86.	0.7	20
457	Intracellular and secreted forms of clusterin are elevated early in Alzheimer's disease and associate with both A $\beta$ and tau pathology. <i>Neurobiology of Aging</i> , 2020, 89, 129-131.	3.1	20
458	Alpha-synuclein activates the classical complement pathway and mediates complement-dependent cell toxicity. <i>Journal of Neuroinflammation</i> , 2021, 18, 177.	7.4	20
459	Application of antiphenylalanine hydroxylase antibodies to the study of the serotonergic system in the human brain. <i>Journal of Chemical Neuroanatomy</i> , 1992, 5, 311-313.	2.2	19
460	Improved Selectivity and Sensitivity in the Visualization of Neurofibrillary Tangles, Plaques and Neuropil Threads. <i>Experimental Neurology</i> , 1996, 5, 177-187.	1.6	19
461	Novel 'inflammatory plaque' pathology in presenilin-1 Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2005, 31, 503-511.	3.2	19
462	The relationship between clinical and pathological variables in Richardson's syndrome. <i>Journal of Neurology</i> , 2012, 259, 482-490.	3.8	19
463	Increased Expression of ABCA8 in Multiple System Atrophy Brain is Associated with Changes in Pathogenic Proteins. <i>Journal of Parkinson's Disease</i> , 2013, 3, 331-339.	2.9	19
464	Long intervening non-coding RNA 00320 is human brain-specific and highly expressed in the cortical white matter. <i>Neurogenetics</i> , 2015, 16, 201-213.	1.5	19
465	Impact of small vessel disease on severity of motor and cognitive impairment in Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2018, 58, 70-74.	1.6	19
466	Tackling clinical heterogeneity across the amyotrophic lateral sclerosis-frontotemporal dementia spectrum using a transdiagnostic approach. <i>Brain Communications</i> , 2021, 3, fcab257.	3.4	19
467	Clinical and Neuropathological Abnormalities in Baboons Treated with HPTP, the Tetrahydropyridine Analog of Haloperidol. <i>Experimental Neurology</i> , 1999, 158, 155-163.	4.1	18
468	Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma. <i>British Journal of Dermatology</i> , 2004, 151, 42-49.	1.7	18

#	ARTICLE	IF	CITATIONS
469	VISA – A pass to innate immunity. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 287-291.	2.9	18
470	The pathogenesis of cingulate atrophy in behavioral variant frontotemporal dementia and Alzheimer’s disease. <i>Acta Neuropathologica Communications</i> , 2013, 1, 30.	5.3	18
471	Predicting Development of Amyotrophic Lateral Sclerosis in Frontotemporal Dementia. <i>Journal of Alzheimer’s Disease</i> , 2017, 58, 163-170.	2.7	18
472	Altered High Density Lipoprotein Composition in Behavioral Variant Frontotemporal Dementia. <i>Frontiers in Neuroscience</i> , 2018, 12, 847.	2.9	18
473	Heritability in frontotemporal tauopathies. <i>Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 115-124.	2.6	18
474	A Comparative Study of Avidin-Biotin-Peroxidase Complexes for the Immunohistochemical Detection of Antigens in Neural Tissue. <i>Biotechnic and Histochemistry</i> , 1992, 67, 367-371.	1.4	17
475	The midbrain dopaminergic cell groups in the baboon <i>papio ursinus</i> . <i>Brain Research Bulletin</i> , 1998, 47, 611-623.	3.0	17
476	Alzheimer’s disease: Its diagnosis and pathogenesis. <i>International Review of Neurobiology</i> , 2001, 48, 167-217.	1.8	17
477	Neuropathology in the S305S tau gene mutation. <i>Brain</i> , 2006, 129, E40-E40.	8.0	17
478	Haplotype analysis of the IGF2 – INS – TH gene cluster in Parkinson’s disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 495-499.	1.8	17
479	Aspects of Innate Immunity and Parkinson’s Disease. <i>Frontiers in Pharmacology</i> , 2012, 3, 33.	3.6	17
480	Pathway Analysis of the Human Brain Transcriptome in Disease. <i>Journal of Molecular Neuroscience</i> , 2013, 51, 28-36.	2.4	17
481	Elevation in Sphingomyelin Synthase Activity Is Associated with Increases in Amyloid-Beta Peptide Generation. <i>PLoS ONE</i> , 2013, 8, e74016.	2.5	17
482	SNCAGene, but NotMAPT, Influences Onset Age of Parkinson’s Disease in Chinese and Australians. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	17
483	Alpha-synuclein: prion or prion-like?. <i>Acta Neuropathologica</i> , 2019, 138, 509-514.	7.9	17
484	Neural mechanisms of psychosis vulnerability and perceptual abnormalities in the ALS – FTD spectrum. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1576-1591.	3.7	17
485	Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson’s Disease Patients. <i>Journal of Parkinson’s Disease</i> , 2021, 11, 1761-1772.	2.9	17
486	Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer’s disease. <i>International Psychogeriatrics</i> , 2009, 21, 688-695.	1.1	16

#	ARTICLE	IF	CITATIONS
487	DATâ€SPECT diagnoses dopamine depletion, but not PD. <i>Movement Disorders</i> , 2014, 29, 1705-1706.	4.3	16
488	Fatty Acid Composition of the Anterior Cingulate Cortex Indicates a High Susceptibility to Lipid Peroxidation in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 175-185.	2.9	16
489	Is <i>CHCHD10</i> Pro34Ser pathogenic for frontotemporal dementia and amyotrophic lateral sclerosis?: Figure 1. <i>Brain</i> , 2015, 138, e385-e385.	8.0	16
490	Oral nicotinamide reduces transepidermal water loss: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2016, 175, 1363-1365.	1.7	16
491	Animal modeling an oligodendrogliaopathy â€“ multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2016, 4, 12.	5.3	16
492	Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice. <i>Neurobiology of Disease</i> , 2018, 120, 76-87.	4.5	16
493	Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degeneration. <i>Neurology</i> , 2019, 92, e2472-e2482.	1.1	16
494	The <i>C9orf72</i> hexanucleotide repeat expansion presents a challenge for testing laboratories and genetic counseling. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 310-316.	2.1	16
495	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. <i>Acta Neuropathologica</i> , 2020, 139, 717-734.	7.9	16
496	Prevalence of chronic traumatic encephalopathy in the Sydney Brain Bank. <i>Brain Communications</i> , 2022, 4, .	3.4	16
497	Interaction between Î±-Synuclein and Tau Genotypes and the Progression of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2011, 1, 271-276.	2.9	15
498	Tenuigenin Attenuates Î±-Synuclein-Induced Cytotoxicity by Down-Regulating Polo-Like Kinase 3. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 688-694.	4.1	15
499	Reductions in COQ2 Expression Relate to Reduced ATP Levels in Multiple System Atrophy Brain. <i>Frontiers in Neuroscience</i> , 2019, 13, 1187.	2.9	15
500	Parkinsonism and cerebrovascular disease. <i>Journal of the Neurological Sciences</i> , 2022, 433, 120011.	0.6	15
501	Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia. <i>Communications Medicine</i> , 2021, 1, .	4.2	15
502	Comparison of the Number of Vasopressin-Producing Hypothalamic Neurons in Rats and Humans. <i>Journal of Neuroendocrinology</i> , 1995, 7, 629-636.	2.6	14
503	Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1004-1011.	4.3	14
504	Brain Banking for Research into Neurodegenerative Disorders and Ageing. <i>Neuroscience Bulletin</i> , 2019, 35, 283-288.	3.5	14

#	ARTICLE	IF	CITATIONS
505	Antihypertensive medications ameliorate Alzheimer's disease pathology by slowing its propagation. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12060.	3.9	14
506	Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months. <i>Neurology</i> , 2021, 97, e1031-e1040.	1.1	14
507	Increased VLCFA-lipids and ELOVL4 underlie neurodegeneration in frontotemporal dementia. <i>Scientific Reports</i> , 2021, 11, 21348.	3.4	14
508	Chronic alcoholism in the absence of Wernicke-Korsakoff syndrome and cirrhosis does not result in the loss of serotonergic neurons from the median raphe nucleus. <i>Metabolic Brain Disease</i> , 1996, 11, 217-227.	2.9	13
509	Identification of families with cortical Lewy body disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2004, 128B, 118-122.	1.8	13
510	Relative preservation of thalamic centromedian nucleus in parkinsonian patients with dystonia. <i>Movement Disorders</i> , 2009, 24, 2128-2135.	4.3	13
511	Tryptophan is a marker of human postmortem brain tissue quality. <i>Journal of Neurochemistry</i> , 2009, 110, 1400-1408.	4.0	13
512	Very early-onset frontotemporal dementia with no family history predicts underlying fused in sarcoma pathology. <i>Brain</i> , 2010, 133, e158-e158.	8.0	13
513	Mutations in protein N-arginine methyltransferases are not the cause of FTL D-FUS. <i>Neurobiology of Aging</i> , 2013, 34, 2235.e11-2235.e13.	3.1	13
514	LRP10 in $\alpha$ -synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1032-1033.	10.3	13
515	Reply: LATE to the PART-y. <i>Brain</i> , 2019, 142, e48-e48.	8.0	13
516	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 75, 223.e1-223.e10.	3.1	13
517	The Neural Signature of Impaired $\Delta$ Tasking in Idiopathic Rapid Eye Movement Sleep Behavior Disorder Patients. <i>Movement Disorders</i> , 2020, 35, 1596-1606.	4.3	13
518	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. <i>Biological Psychiatry</i> , 2021, 89, 825-835.	1.3	13
519	Early white matter pathology in the fornix of the limbic system in Huntington disease. <i>Acta Neuropathologica</i> , 2021, 142, 791-806.	7.9	13
520	Differences in Sex Distribution Between Genetic and Sporadic Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1153-1161.	2.7	13
521	Short tandem repeat expansions in sporadic amyotrophic lateral sclerosis and frontotemporal dementia. <i>Science Advances</i> , 2023, 9, .	10.8	13
522	Brain stem nuclei in sudden infant death syndrome (SIDS): volumes, neuronal numbers and positions. <i>Neuropathology and Applied Neurobiology</i> , 1995, 21, 262-268.	3.2	12

#	ARTICLE	IF	CITATIONS
523	Parkinson's disease with late Pick's dementia. <i>Movement Disorders</i> , 2001, 16, 311-319.	4.3	12
524	Partial lesion of thalamic ventral intermediate nucleus after chronic high-frequency stimulation. <i>Movement Disorders</i> , 2004, 19, 709-711.	4.3	12
525	Relationship between neuronal loss and ?inflammatory plaques? in early onset Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2007, 33, 328-333.	3.2	12
526	Role of hippocalcin in mediating A $\beta$ toxicity. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 1247-1257.	3.8	12
527	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	3.1	12
528	Quantification of Total and Mutant Huntingtin Protein Levels in Biospecimens Using a Novel alphaLISA Assay. <i>ENeuro</i> , 2018, 5, ENEURO.0234-18.2018.	1.9	12
529	Impaired Color Discriminationâ€”A Specific Marker of Hallucinations in Lewy Body Disorders. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2019, 32, 257-264.	2.5	12
530	Accelerated loss of hypoxia response in zebrafish with familial Alzheimerâ€™s disease-like mutation of presenilin 1. <i>Human Molecular Genetics</i> , 2020, 29, 2379-2394.	3.0	12
531	Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinsonâ€™s Disease Patient Monocytes and Inversely Correlates with Motor Severity. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1157-1165.	2.9	12
532	Electron microscopic analysis of the mesencephalic ventromedial tegmentum in the cat. <i>Journal of Comparative Neurology</i> , 1984, 230, 393-412.	1.9	11
533	Anatomical and immunohistochemical identification of catecholaminergic neurones in brain slice preparations used in electrophysiology. <i>Journal of Neuroscience Methods</i> , 1996, 64, 83-93.	2.6	11
534	The midbrainâ€”pons ratio distinguishes progressive supranuclear palsy from nonâ€”fluent primary progressive aphasia. <i>European Journal of Neurology</i> , 2017, 24, 956-965.	3.5	11
535	CNS cell typeâ€”specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. <i>Journal of Biological Chemistry</i> , 2019, 294, 14149-14162.	3.5	11
536	LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. <i>Neurobiology of Disease</i> , 2020, 144, 105049.	4.5	11
537	Prion-like $\alpha$ -synuclein pathology in the brain of infants with Krabbe disease. <i>Brain</i> , 2022, 145, 1257-1263.	8.0	11
538	Common Variants Near <sc>ZIC1</sc> and <sc>ZIC4</sc> in Autopsyâ€”Confirmed Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 2110-2121.	4.3	11
539	Substance P-like immunoreactive fibres in the ventromedial mesencephalic tegmentum of rat. <i>Brain Research Bulletin</i> , 1988, 21, 659-670.	3.0	10
540	Mitochondrial ultrastructure and density in a primate model of persistent tardive dyskinesia. <i>Life Sciences</i> , 2000, 66, 1345-1350.	4.4	10

#	ARTICLE	IF	CITATIONS
541	The Serotonin and Tachykinin Systems. , 2004, , 1205-1256.		10
542	Insoluble $\alpha$ -synuclein in alzheimer's disease without lewy body formation. Neurotoxicity Research, 2005, 7, 69-76.	2.7	10
543	Investigation of the lipid component of neuromelanin. Journal of Neural Transmission, 2006, 113, 735-739.	2.9	10
544	Clarifying the pathological progression of Parkinson's disease. Acta Neuropathologica, 2008, 115, 377-378.	7.9	10
545	Endogenous progesterone levels and frontotemporal dementia: modulation of TDP-43 and Tau levels <i>in vitro</i> and treatment of the A315T TARDBP mouse model. DMM Disease Models and Mechanisms, 2013, 6, 1198-204.	2.4	10
546	Prodegenerative $\beta$ -galactosidase expression in oligodendroglial $\alpha$ -synuclein models of multiple system atrophy. Neurobiology of Disease, 2014, 63, 171-183.	4.5	10
547	The role of transcriptional control in multiple system atrophy. Neurobiology of Aging, 2015, 36, 394-400.	3.1	10
548	TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in behavioral variant frontotemporal dementia. Journal of the Neurological Sciences, 2016, 366, 197-201.	0.6	10
549	Clinical Aspects of Alzheimer's Disease. Advances in Neurobiology, 2017, 15, 31-53.	0.0	10
550	Multiple neuronal pathologies are common in young patients with pathologically proven Frontotemporal lobar degeneration. Neuropathology and Applied Neurobiology, 2018, 44, 522-532.	3.2	10
551	Von Economo Neurons in Behavioral Variant Frontotemporal Dementia with Underlying Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 963-967.	2.7	10
552	Hypothalamic symptoms of frontotemporal dementia disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 182, 269-280.	0.3	10
553	Thalamic vacuolation in acute Wernicke's encephalopathy. Metabolic Brain Disease, 1993, 8, 107-113.	2.9	9
554	Prediction of minimal erythema dose with a reflectance melanin meter. British Journal of Dermatology, 1997, 136, 714-718.	1.7	9
555	A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease. Neuroscience Letters, 2007, 414, 170-173.	2.1	9
556	Exploring the Phenotype in Mild Cognitive Impairment to Aid the Prediction of Those at Risk of Transitioning to Parkinson Disease and Dementia With Lewy Bodies. Journal of Geriatric Psychiatry and Neurology, 2017, 30, 196-205.	2.5	9
557	Intrafamilial Phenotypic Variability in the C9orf72 Gene Expansion: 2 Case Studies. Frontiers in Psychology, 2018, 9, 1615.	2.2	9
558	The complex relationship between genotype, pathology and phenotype in familial dementia. Neurobiology of Disease, 2020, 145, 105082.	4.5	9



#	ARTICLE	IF	CITATIONS
559	Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 162-171.	6.0	9
560	Effect of PSEN1 mutations on MAPT methylation in early-onset Alzheimer's disease. <i>Current Alzheimer Research</i> , 2015, 12, 745-751.	1.5	9
561	Identifying gene expression profiles associated with neurogenesis and inflammation in the human subependymal zone from development through aging. <i>Scientific Reports</i> , 2022, 12, 40.	3.4	9
562	Thalamic and Cerebellar Regional Involvement across the ALS-FTD Spectrum and the Effect of C9orf72. <i>Brain Sciences</i> , 2022, 12, 336.	2.4	9
563	Distribution Patterns of Astrocyte Populations in the Human Cortex. <i>Neurochemical Research</i> , 2023, 48, 1222-1232.	3.3	9
564	Neurofilament-Immunoreactive Neurons Are Not Selectively Vulnerable in Alzheimer's Disease. <i>Neurobiology of Disease</i> , 2001, 8, 136-146.	4.5	8
565	Overview and recent advances in neuropathology. Part 2: Neurodegeneration. <i>Pathology</i> , 2011, 43, 93-102.	0.7	8
566	Selective Spatiotemporal Vulnerability of Central Nervous System Neurons to Pathologic TAR DNA-Binding Protein 43 in Aged Transgenic Mice. <i>American Journal of Pathology</i> , 2018, 188, 1447-1456.	4.1	8
567	Alzheimer's amyloid $\beta$ and tau protein accumulation is associated with decreased expression of the LDL receptor-associated protein in human brain tissue. <i>Brain and Behavior</i> , 2020, 10, e01672.	2.3	8
568	Prodromal neuroinvasion of pathological $\beta$ -synuclein in brainstem reticular nuclei and white matter lesions in a model of $\beta$ -synucleinopathy. <i>Brain Communications</i> , 2021, 3, fcab104.	3.4	8
569	Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation. <i>Neurobiology of Disease</i> , 2021, 157, 105426.	4.5	8
570	Ubiquitin-positive achromatic neurons in corticobasal degeneration. <i>Acta Neuropathologica</i> , 1995, 90, 68-75.	7.9	8
571	The contribution of brain banks to knowledge discovery in amyotrophic lateral sclerosis: A systematic review. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	8
572	Microwave Modification of the Methenamine Silver Technique for the Demonstration of Alzheimer-Type Pathology. <i>Journal of Histotechnology</i> , 1996, 19, 33-38.	0.7	7
573	Utilising Molecular Biological and Histopathological Techniques to Study the Dopaminergic System in Patients with Melancholia. <i>Australian and New Zealand Journal of Psychiatry</i> , 1997, 31, 27-35.	2.7	7
574	Tau isoform expression in frontotemporal dementia without tau deposition. <i>Journal of Clinical Neuroscience</i> , 2007, 14, 1182-1185.	1.6	7
575	Clinicopathological aspects of motor parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S208-S210.	2.2	7
576	An evidence base for noradrenergic deficits in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1589-1591.	4.3	7

#	ARTICLE	IF	CITATIONS
577	Early-life decline in neurogenesis markers and age-related changes of TrkB splice variant expression in the human subependymal zone. <i>European Journal of Neuroscience</i> , 2017, 46, 1768-1778.	3.5	7
578	Evaluating the Sustained Attention Response Task to Quantify Cognitive Fluctuations in Dementia With Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 333-339.	2.5	7
579	Native Separation and Metallation Analysis of SOD1 Protein from the Human Central Nervous System: a Methodological Workflow. <i>Analytical Chemistry</i> , 2021, 93, 11108-11115.	6.7	7
580	A small molecule toll-like receptor antagonist rescues $\alpha$ -synuclein fibril pathology. <i>Journal of Biological Chemistry</i> , 2022, 298, 102260.	3.5	7
581	NORADRENERGIC LOCUS COERULEUS NEURONS. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 191-192.	2.5	6
582	Pathology of Parkinson's Disease. <i>Blue Books of Neurology</i> , 2010, 34, 132-154.	0.0	6
583	Hallucinogenic mechanisms: pathological and pharmacological insights. , 2015, , 119-149.		6
584	Coexisting Lewy body disease and clinical parkinsonism in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 2192-2199.	3.5	6
585	Degeneration of the central median parafascicular complex in Parkinson's disease. <i>Annals of Neurology</i> , 2000, 47, 345-352.	5.8	6
586	Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr $\alpha$ -synuclein mutation. <i>Annals of Neurology</i> , 2001, 49, 313-319.	5.8	6
587	Factors That Influence Non-Motor Impairment Across the ALS-FTD Spectrum: Impact of Phenotype, Sex, Age, Onset and Disease Stage. <i>Frontiers in Neurology</i> , 2021, 12, 743688.	2.5	6
588	Dynamic network impairments underlie cognitive fluctuations in Lewy body dementia. <i>Npj Parkinson's Disease</i> , 2022, 8, 16.	5.4	6
589	Utility of the Addenbrooke's Cognitive Examination III online calculator to differentiate the primary progressive aphasia variants. <i>Brain Communications</i> , 2022, 4, .	3.4	6
590	Role of Oligodendrocyte Lineage Cells in Multiple System Atrophy. <i>Cells</i> , 2023, 12, 739.	4.2	6
591	Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS. <i>Neuropathology and Applied Neurobiology</i> , 2023, 49, .	3.2	6
592	Sunscreens and vitamin E provide some protection to the skin immune system from solar-simulated UV radiation. <i>Australasian Journal of Dermatology</i> , 1998, 39, 71-75.	0.8	5
593	Early in vivo Effects of the Human Mutant Amyloid- $\beta$ Protein Precursor (hA $\beta$ 2PPSwInd) on the Mouse Olfactory Bulb. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 443-457.	2.7	5
594	Increased aneuploidy is not a universal feature across $\alpha$ -synucleinopathies. <i>Movement Disorders</i> , 2017, 32, 475-476.	4.3	5

#	ARTICLE	IF	CITATIONS
595	Deletion of Alzheimer's Disease Risk Gene ABCA7 Alters White Adipose Tissue Development and Leptin Levels. <i>Journal of Alzheimer's Disease Reports</i> , 2017, 1, 237-247.	2.3	5
596	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020, 10, 12184.	3.4	5
597	Globular glial tauopathy with a mutation in MAPT and unusual TDP-43 proteinopathy in a patient with behavioural-variant frontotemporal dementia. <i>Acta Neuropathologica</i> , 2021, 141, 791-794.	7.9	5
598	Lipid content determines aggregation of neuromelanin granules in vitro. , 2007, , 35-38.		5
599	Neurotransmitter Changes in Alzheimer's Disease. <i>Advances in Behavioral Biology</i> , 1995, , 199-219.	0.0	5
600	Narrow doorways alter brain connectivity and step patterns in isolated REM sleep behaviour disorder. <i>NeuroImage: Clinical</i> , 2022, 33, 102958.	2.8	5
601	Examining the presence and nature of delusions in Alzheimer's disease and frontotemporal dementia syndromes. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	2.6	5
602	Overlap between Central and Peripheral Transcriptomes in Parkinson's Disease but Not Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5200.	4.2	5
603	Past antihypertensive medication use is associated with lower levels of small vessel disease and lower A $\beta$ 2 plaque stage in the brains of older individuals. <i>Neuropathology and Applied Neurobiology</i> , 2023, 49, .	3.2	5
604	Preserved Cognition and Functional Independence after a Large Right Posterior Cerebral Artery Infarct: Longitudinal Clinical and Neuropathological Findings. <i>Neurocase</i> , 2006, 12, 81-90.	0.7	4
605	Pigmentation in the human brain and risk of Parkinson's disease. <i>Annals of Neurology</i> , 2010, 67, 553-554.	5.8	4
606	Unlocking the Secrets of Lrrk2 Function With Selective Kinase Inhibitors. <i>Future Neurology</i> , 2013, 8, 347-357.	0.5	4
607	Restricted disease propagation in multiple system atrophy with prolonged survival. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 681-685.	3.2	4
608	Are mutations in <i>MAPT</i> associated with GGT type III?. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 406-409.	3.2	4
609	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. <i>Annals of Neurology</i> , 2000, 47, 718-728.	5.8	4
610	Alpha Synuclein in Parkinson's Disease. , 2014, , 691-726.		4
611	Diagnostic evaluation of the substantia nigra. <i>Neuropathology and Applied Neurobiology</i> , 1996, 22, 228-232.	3.2	4
612	Microwave Modification of the Methenamine Silver Technique for the Demonstration of Alzheimer-Type Pathology. <i>Journal of Histotechnology</i> , 1996, 19, 33-38.	0.7	4

#	ARTICLE	IF	CITATIONS
613	Limbic thalamus atrophy is associated with visual hallucinations in Lewy body disorders. <i>Neurobiology of Aging</i> , 2022, 112, 122-128.	3.1	4
614	Analysis of staining methods for different cortical plaques in Alzheimer's disease. <i>Acta Neuropathologica</i> , 1994, 87, 174-186.	7.9	4
615	Sex-specific lipid dysregulation in the <i>Abca7</i> knockout mouse brain. <i>Brain Communications</i> , 2022, 4, .	3.4	4
616	Multiple pathways of lipid dysregulation in amyotrophic lateral sclerosis. <i>Brain Communications</i> , 2022, 5, .	3.4	4
617	A potential patient stratification biomarker for Parkinson's disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells. <i>Npj Parkinson's Disease</i> , 2024, 10, .	5.4	4
618	Diagnostic evaluation of the substantia nigra. <i>Neuropathology and Applied Neurobiology</i> , 1996, 22, 228-232.	3.2	3
619	Neuropathology of three clinical cases prospectively diagnosed as dementia with Lewy bodies. <i>Journal of Clinical Neuroscience</i> , 1999, 6, 149-154.	1.6	3
620	Clarifying Lewy-body parkinsonism with visual hallucinations. <i>Lancet Neurology</i> , The, 2005, 4, 588-589.	10.3	3
621	Anticipation of onset age in familial Parkinson's disease without SCA gene mutations. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 309-313.	2.2	3
622	P1-039: MAPT METHYLATION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2014, 10, P317-P318.	0.7	3
623	Reply: Will FTD-tau work for all when FTDP-17 retires?. <i>Brain</i> , 2018, 141, e63-e63.	8.0	3
624	A Neuroethics Framework for the Australian Brain Initiative. <i>Neuron</i> , 2020, 105, 201.	8.0	3
625	The Role of Astrocytes in Parkinson's Disease. , 2014, , 127-144.		3
626	Neglected cytotoxic T cell invasion of the brain: how specific for Parkinson's disease?. <i>Brain</i> , 2020, 143, 3518-3521.	8.0	3
627	Flow Cytometry Measurement of Glucocerebrosidase Activity in Human Monocytes. <i>Bio-protocol</i> , 2020, 10, e3572.	0.4	3
628	Cerebellar integrity and contributions to cognition in C9orf72-mediated frontotemporal dementia. <i>Cortex</i> , 2022, 149, 73-84.	2.7	3
629	Schizotypal traits across the amyotrophic lateral sclerosis-frontotemporal dementia spectrum: pathomechanistic insights. <i>Journal of Neurology</i> , 2022, 269, 4241-4252.	3.8	3
630	An Adaptive Measure of Visuospatial Impairment in Dementia with Lewy Bodies. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 619-627.	1.7	3

#	ARTICLE	IF	CITATIONS
631	The emergence of proto-objects in complex visual hallucinations. Behavioral and Brain Sciences, 2005, 28, 767-768.	0.7	2
632	Cortical limb myoclonus in pathologically proven progressive supranuclear palsy. Movement Disorders, 2013, 28, 1804-1806.	4.3	2
633	Misfolded proteins in Huntington disease fetal grafts: Further evidence of cell-to-cell transfer?. Annals of Neurology, 2014, 76, 20-21.	5.8	2
634	F2-03-04: Genetic risk factors for posterior cortical atrophy. Alzheimer's and Dementia, 2015, 11, P168-P169.	0.7	2
635	The Differentiation of Progressive Supranuclear Palsy. Neurodegenerative Disease Management, 2015, 5, 385-388.	2.3	2
636	Authors' response to a reply to "A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients". British Journal of Dermatology, 2017, 176, 552-553.	1.7	2
637	Evaluating a novel behavioral paradigm for visual hallucinations in Dementia with Lewy bodies. Aging Brain, 2021, 1, 100011.	1.5	2
638	Anterior-posterior electrophysiological activity characterizes Parkinsonian visual misperceptions. Neurology and Clinical Neuroscience, 2021, 9, 312-318.	0.4	2
639	Glycoprotein Pathways Altered in Frontotemporal Dementia With Autoimmune Disease. Frontiers in Immunology, 2021, 12, 736260.	4.8	2
640	Ascending Noradrenergic and Serotonergic Systems in the Human Brainstem. Advances in Behavioral Biology, 1995, , 155-171.	0.0	2
641	Pattern of Midbrain Pathology in Different Parkinsonian Syndromes. Advances in Behavioral Biology, 1996, , 441-444.	0.0	2
642	Exploring the Sensitivity of Prodromal Dementia with Lewy Bodies Research Criteria. Brain Sciences, 2022, 12, 1594.	2.4	2
643	Riluzole is associated with decreasing neuritic plaque severity in amyotrophic lateral sclerosis. Brain, 2023, 146, e17-e19.	8.0	2
644	Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach. Movement Disorders, 2024, 39, 462-471.	4.3	2
645	Motor deficits associated with changes in $\hat{\alpha}$ -amyloid in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 475-476.	6.0	1
646	Unusual $\hat{\alpha}$ -synuclein and cerebellar pathologies in a case of hereditary myoclonus-dystonia without <i>SCG10</i> mutation. Neuropathology and Applied Neurobiology, 2015, 41, 837-842.	3.2	1
647	Reply: Lysosomal dysfunction in Parkinson's disease. Brain, 2015, 138, e340-e340.	8.0	1
648	A Practical Approach to Differentiate the Frontotemporal Tauopathy Subtypes. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1122-1126.	1.8	1

#	ARTICLE	IF	CITATIONS
649	Amyotrophic lateral sclerosis features predict TDP-43 pathology in frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2021, 107, 11-20.	3.1	1
650	Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. <i>Annals of Neurology</i> , 2000, 47, 718.	5.8	1
651	Variable Phenotype of Alzheimer's Disease with Spastic Paraparesis. <i>Research and Perspectives in Alzheimer's Disease</i> , 2005, , 73-92.	0.0	1
652	Cytoarchitecture and Chemistry of Midbrain Dopaminergic Cell Groups. <i>Advances in Behavioral Biology</i> , 1995, , 115-127.	0.0	1
653	A protective role of ABCA5 in response to elevated sphingomyelin levels in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2024, 10, .	5.4	1
654	Carcinogen-Treated Skin Allografts Rejected by T Lymphocytes Specific for Class I but Not Class II MHC Antigens. <i>Cellular Immunology</i> , 1993, 151, 291-299.	3.0	0
655	ORGANIZATION: PYRAMIDAL AND EXTRAPYRAMIDAL SYSTEM. , 2007, , 396-401.		0
656	O.064 Thalamic changes in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S17.	2.2	0
657	P3.061 Differential distribution of tyrosine hydroxylase isoforms in the human brain. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S164.	2.2	0
658	Reply to: "Being too inclusive about synuclein inclusions". <i>Nature Medicine</i> , 2010, 16, 961-961.	29.9	0
659	Analysis of Tyrosine Hydroxylase Isoforms and Phosphorylation in Parkinson's Disease. , 2014, , 15.		0
660	Progressive supranuclear palsy finally has a clinically measurable $\alpha$ abnormality. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 241-241.	6.0	0
661	[S3"01"01]: MIXED PATHOLOGY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P877.	0.7	0
662	White matter changes in frontotemporal dementia and the C9ORF72 gene expansions. <i>Journal of the Neurological Sciences</i> , 2017, 381, 803.	0.6	0
663	P1405: VISUAL ASSESSMENT OF $\beta$ AMYLOID PET SCAN IS IMPROVED BY CAPAIBL. <i>Alzheimer's and Dementia</i> , 2018, 14, P459.	0.7	0
664	A52...SIRT1 is increased in affected brain regions in huntington disease impacting hypothalamic metabolic pathways. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, , .	6.0	0
665	Invited Reply to: "Instrumental Analysis of Gait Abnormalities in Idiopathic Rapid Eye Movement Sleep Behavior Disorder". <i>Movement Disorders</i> , 2020, 35, 195-196.	4.3	0
666	The aging brain and brain banking. , 2021, , 103-112.		0

#	ARTICLE	IF	CITATIONS
667	Which Basal Ganglia Surgical Targets Ameliorate Parkinsonian Symptoms?. <i>Advances in Behavioral Biology</i> , 2002, , 533-542.	0.0	0
668	Cytoarchitecture and Chemistry of the Human Ascending Cholinergic System. <i>Advances in Behavioral Biology</i> , 1995, , 129-153.	0.0	0
669	Thalamic and Cortical Changes in Parkinsonian Disorders. , 2005, , 415-424.		0
670	Physiologic and Neurotoxic Properties of A $\beta$ Peptides. , 2007, , 179-197.		0
671	Chemoselective Bioconjugation of Amyloidogenic Protein Antigens to PEGylated Microspheres Enables Detection of $\beta$ -Synuclein Autoantibodies in Human Plasma. <i>Bioconjugate Chemistry</i> , 2022, , .	3.8	0
672	Presence of co $\alpha$ -pathology in sporadic early $\alpha$ -onset Alzheimer disease versus dominantly inherited Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2021, 17, e055045.	0.7	0
673	Effects of STN/SNr deep brain stimulation in a case of progressive supranuclear palsy with a Parkinson disease phenotype. <i>Journal of Neuropathology and Experimental Neurology</i> , 2023, 82, 821-823.	1.8	0
674	The importance of patient $\alpha$ -centred drug development for amyotrophic lateral sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2023, 49, .	3.2	0
675	An attentional and working memory theory of hallucination vulnerability in frontotemporal dementia. <i>Brain Communications</i> , 2024, 6, .	3.4	0
676	Research Priorities on the Role of $\beta$ -Synuclein in Parkinson's Disease Pathogenesis. <i>Movement Disorders</i> , 0, , .	4.3	0